VJHemOnc is committed to improving our service to you

ASH 2019 | Molecular therapy stratification for high-risk MM: MUK Nine b OPTIMUM

VJHemOnc is committed to improving our service to you

Martin Kaiser

Martin Kaiser, MD, Royal Marsden NHS Foundation Trust, London, UK, discusses the MUK Nine b: OPTIMUM Treatment Protocol (NCT03188172), a phase II trial for transplant eligible newly diagnosed multiple myeloma (NDMM) patients. This study consisted of two inter-related protocols: a molecular screening protocol and an interventional trial for high-risk NDMM identified in the molecular screening. Dr Kaiser highlights the innovative therapy used in this trial. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter